Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial
Sponsor: UZ Leuven
Phase: 1, 2
Disease: Gastroesophageal adenocarcinoma, Esophageal adenocarcinoma, Gastroesophageal junction adenocarcinoma, Gastric adenocarcinoma
EU trial number: 2025-523483-20-00
Population: Adults with previously untreated, histologically confirmed HER2-positive localized, resectable or operable gastroesophageal adenocarcinoma who are fit for perioperative chemotherapy and surgery, with ECOG performance status 0–1.
Register Investigator Interest
Interested in offering this trial to suitable patients?